Durata Therapeutics, Inc. (DRTX)
-NasdaqGM 7.08 
0.03(0.44%) 10:49AM EDT - Nasdaq Real Time Price
| Prev Close: | 7.11 |
|---|
| Open: | 7.14 |
|---|
| Bid: | 7.05 x 2000 |
|---|
| Ask: | 7.10 x 400 |
|---|
| 1y Target Est: | 15.25 |
|---|
| Beta: | 1.824 |
|---|
| Next Earnings Date: | 8-Jul-13 |
|---|
| Day's Range: | 7.03 - 7.17 |
|---|
| 52wk Range: | 6.65 - 10.63 |
|---|
| Volume: | 5,007 |
|---|
| Avg Vol (3m): | 70,865 |
|---|
| Market Cap: | 188.49M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -5.41 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- DURATA THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Fri, May 17)
- DURATA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 17)
- Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of DirectorsGlobeNewswire(Thu, May 16)
- Durata Therapeutics, Inc. Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu, May 9)
- DURATA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Thu, May 9)
- Durata Therapeutics to Present at Bank of America Merrill Lynch 2013 Healthcare ConferenceGlobeNewswire(Tue, May 7)
- Wall Street Transcript Interview with Dr. Jason Kantor, Research Analyst at Credit Suisse Group: High Success Rates and Significant M&A in the Antibody SpaceWall Street Transcript(Fri, May 3)
- Durata Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013GlobeNewswire(Thu, May 2)
- Durata Therapeutics announces Phase 1 study data on dalbavancinat theflyonthewall.com(Mon, Apr 29)
- New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID MeetingGlobeNewswire(Mon, Apr 29)
- Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID MeetingGlobeNewswire(Mon, Apr 29)
- [$$] Previewat Barrons.com(Sat, Apr 27)
- Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID MeetingGlobeNewswire(Wed, Apr 24)
- Durata Therapeutics to Present at the 2013 Needham Healthcare ConferenceGlobeNewswire(Mon, Apr 22)
- Durata Therapeutics Closes Public Offering of Common StockGlobeNewswire(Wed, Apr 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.22 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.52 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.
View More